News

The FDA acceptance was based on the comparability data of Mesoblast’s initial set of manufacturing runs for clinical product to be used in the upcoming Phase 3 trial

The company is involved in developing and manufacturing nasal and pulmonary drug delivery devices. In 2000 Pardonge served as R&D manager for Aptar Pharma’s prescription division and promoted

Net sales for third quarter of 2012 were $9.97m compared to $24.78m for the third quarter of 2011. The company reported a net loss of $13.25m, or $1.41

The patients in single arm open label extension study were given autologous stem cell transplant along with modified T cells. The clinical trial, which enrolled 6 patients, aimed

The Good Laboratory Practice compliant facility received all statutory approvals from the Atomic Energy Review Board of India to conduct 3H and 14C synthesis. GVK BIO CEO Manni

Exjade is used to treat chronic iron overload requiring chelation therapy when deferoxamine therapy is insufficient in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndromes.

Orexo, which expects the Zubsolv approval in July 2013, schedules the launch for September 2013. Orexo president and CEO Anders Lundstrom said, "We have a good chance of

The swab will quantitatively measure the fetal fibronectin (fFN), a protein, which will help finding out whether a woman is likely to give birth prematurely or not. The

The CHMP opinion indicates the use of the broad coverage vaccine in individuals older than two months. Novartis vaccines and diagnostics division head Andrin Oswald said Bexsero represents